Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Sector: Medicinal Chemicals & Botanical Products
Industry: Biotechnology
Definium Therapeutics, Inc.
NASDAQ:DFTXHealthcare · Biotechnology
PrePre-market+0.12%$33.31
Close$33.27+0.45%AH$33.42-0.33%Now$33.31
Close$33.27+9.59%AH$33.42-0.33%since
Mkt Cap$4.47B
Float132.23M
O/S134.37M
PM VOL1K sh
$ Vol≈$43K
RVOL4.96×
Inst Own86.3%
SI7.6%
Dilution